Gelteq Limited GELS

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
23/100
Weak

About Gelteq Limited

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia. Full GELS analysis →

Competitive advantage assessment

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.00), suggesting weak customer stickiness.
  • Below-Peer Operating Efficiency Operating margin at 7.5th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
19

Where GELS ranks in Drug Manufacturers - Specialty & Generic

Gelteq Limited ranks #73 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 80%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near GELS in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
69 Citius Oncology, Inc. CTOR 27/100 Developing
70 Aquestive Therapeutics, Inc. AQST 26/100 Developing
71 China SXT Pharmaceuticals, Inc. SXTC 26/100 Developing
72 Petros Pharmaceuticals, Inc. PTPI 25/100 Developing
73 Gelteq Limited GELS 23/100 Weak
74 BioAge Labs, Inc. BIOA 20/100 Weak
75 Cyclo Therapeutics, Inc. CYTHW 19/100 Weak
76 InMed Pharmaceuticals Inc. INM 19/100 Weak
77 Quantum Biopharma Ltd. QNTM 17/100 Weak

See every Pharma / Mature Biotech company ranked by moat score →

How GELS scores on the Corporate Default defenses

Pricing Power

Score 19 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 8 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 8 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 32 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 29 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 34 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding GELS's moat

What is Gelteq Limited's moat score?

Gelteq Limited (GELS) scores 23 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #73 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 80%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (34/100) and its weakest is Customer Stickiness (8/100).

How does Gelteq Limited compare with other Drug Manufacturers - Specialty & Generic companies?

Gelteq Limited ranks #73 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Petros Pharmaceuticals, Inc. (PTPI) at 25 just above it and BioAge Labs, Inc. (BIOA) at 20 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Gelteq Limited scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Gelteq Limited?

The Corporate Default template measures 6 defenses, and GELS scores: Pricing Power (19), Cost Advantage (8), Customer Stickiness (8), Capital Efficiency (32), Resilience (29), Scale & Market Position (34). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000